Sökning: WFRF:(Baecklund Eva) >
Expression of PD-1,...
-
Hellbacher, ErikUppsala universitet,Reumatologi
(författare)
Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases-A Possible Association with High Rheumatoid Arthritis Disease Activity
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-03-15
-
MDPI,2022
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-472740
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-472740URI
-
https://doi.org/10.3390/cancers14061509DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Simple Summary Immunotherapy blocking programmed cell death protein 1 (PD-1) and its ligands (PD-L1, PD-L2) is less effective in non-Hodgkin lymphoma (NHL) than classical Hodgkin lymphoma. However, NHL is a heterogeneous group and current research seeks to identify subgroups of NHL patients responsive to PD-1 blocking agents. Whether patients with pre-existing rheumatic diseases might constitute such a subgroup is unknown. We investigated the expression of PD-1 and its ligands in lymphoma patients with pre-existing rheumatic diseases. Our key findings include that in patients with pre-existing rheumatoid arthritis (RA) and subsequent diffuse large B-cell lymphoma, an association between RA disease severity and increased expression of PD-L1 in tumor cells was seen. This warrants further studies of the PD-1 pathway in lymphoma in other chronic inflammatory conditions. Current research seeks to identify subgroups of non-Hodgkin lymphoma (NHL) patients responsive to PD-1 blocking agents. Whether patients with pre-existing rheumatic diseases might constitute such a subgroup is unknown. We determined intratumoral expression of PD-1 and its ligands in lymphoma patients with pre-existing rheumatic diseases. We included 215 patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) or Sjogren's syndrome with subsequent lymphoma and 74 diffuse large B-cell lymphoma (DLBCL) controls without rheumatic disease. PD-1 and PD-ligand immunohistochemical markers were applied on tumor tissue microarrays. The number of PD-1+ tumor infiltrating leukocytes (TILs) and proportions of PD-L1+ and PD-L2+ tumor cells and TILs were calculated and correlated with clinical data. Expression of PD-L1 in tumor cells and TILs was highest in classical Hodgkin lymphoma and DLBCL. In DLBCLs, expression of PD-1 in TILs and PD-L1 in tumor cells was similar in RA, SLE and controls. In RA-DLBCL, high expression of PD-L1 in tumor cells was significantly more common in patients with the most severe RA disease and was associated with inferior overall survival in multivariable analysis.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Sundström, ChristerUppsala universitet,Experimentell och klinisk onkologi,Klinisk och experimentell patologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)chrisund
(författare)
-
Molin, Daniel,1969-Uppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)danimoli
(författare)
-
Baecklund, Eva,1956-Uppsala universitet,Reumatologi,Science for Life Laboratory, SciLifeLab(Swepub:uu)evaba786
(författare)
-
Hollander, PeterUppsala universitet,Experimentell och klinisk onkologi,Klinisk och experimentell patologi(Swepub:uu)petho189
(författare)
-
Uppsala universitetReumatologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancers: MDPI14:62072-6694
Internetlänk
Hitta via bibliotek
-
Cancers
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas